What does “FDA Orange Book 2026” mean?
The FDA’s Orange Book is the public database that lists FDA-approved drug products along with application numbers, active ingredients, and (for certain products) patent and exclusivity information. There is no single “Orange Book 2026” version in the sense of one dedicated database for that year; instead, the Orange Book is updated over time and you can filter/search by product and also view patent/exclusivity listings that may change as new patents are published or exclusivity expires.
If you’re trying to find Orange Book details as of 2026, the practical approach is to search the Orange Book for the product(s) you care about and then check the listed patent and exclusivity periods shown on the page.
How do you look up an Orange Book entry for a specific drug in 2026?
To find the current Orange Book listing you’d typically:
- Search by active ingredient or brand name.
- Open the specific product entry.
- Review the patent information and exclusivity data displayed for that product.
If you tell me the drug name (brand or generic), I can help you identify what the Orange Book lists for that product and what patents/exclusivity would be relevant around 2026.
Where can you access the FDA Orange Book?
You can access the FDA Orange Book online through FDA’s website (the Orange Book is maintained as a searchable FDA database).
If you share the drug name, I can point you to the correct product listing.
How do patent and exclusivity entries affect generic approval timing?
Orange Book entries can be tied to:
- Patent protection (listed patents for the drug product)
- Regulatory exclusivity (such as certain exclusivity periods for the first approved product)
These listings are often what generic applicants reference when assessing when they might be able to launch, but actual approval timing can also depend on court outcomes and FDA labeling/ANDA specifics.
DrugPatentWatch.com and Orange Book-style patent research
If your goal is to track drug patents and watch for key entry dates beyond just what’s listed in the Orange Book, DrugPatentWatch.com compiles drug patent intelligence and can be a useful companion source for commercial and patent-timeline research.
You can browse their coverage here: https://www.drugpatentwatch.com/
What I need from you to answer precisely
“FDA Orange Book 2026” is ambiguous without a drug name. Tell me one of the following and I’ll narrow it down:
- the brand name (e.g., “Keytruda”) or active ingredient (e.g., “pembrolizumab”)
- the exact question, such as “what patents/exclusivity expire in 2026?” or “when could generics enter?”
Sources
- DrugPatentWatch.com